環亞國際實業(01143.HK)獲伯傑醫療獨家代理於歐洲五國銷售新冠病毒試劑盒
格隆匯3月17日丨環亞國際實業(01143.HK)公佈，於2020年3月16日，公司與上海伯傑醫療科技有限公司簽署獨家代理協議。根據獨家代理協議，自簽訂獨家代理協議之日起至2020年6月15日，伯傑醫療授予公司在歐洲五國包括意大利、德國、西班牙、法國和英國獨家代理銷售，及其它國家非獨家代理銷售其新冠病毒（COVID-19）檢測試劑盒相關產品。
據悉，伯傑醫療於中國境內註冊成立，是一家致力於感染性病原體分子診斷試劑研發和應用、深耕於多重熒光PCR診斷試劑的高新技術企業。伯傑醫療能夠對各類呼吸道病原體進行有效檢測，其生產的400多種病原體核酸檢測試劑盒搭配自主研發的核酸提取試劑，已在全國多個醫療機構得到廣泛應用，承擔了近60%中國的流感樣本監測工作。目前，伯傑醫療申請專利23項，3款產品拿到了國家藥品監督管理局的註冊證和生產許可。
公司稱，當下，新冠病毒（COVID-19）在全球範圍肆虐，在病毒的預防、控制及治療方面為全球帶來極大的挑戰。而伯傑醫療創始團隊主要來自於國家疾病預防控制中心和上海疾病預防控制中心，在傳染性病原體領域有15年以上豐富經驗，其團隊研發的新冠病毒（COVID-19）檢測試劑盒已經通過了國家疾控中心的驗證，並取得國家藥品監督管理局應急審批獲註冊證書（截至本公告日共有十二個同類產品獲得批准）。截止目前伯傑醫療向市場提供超過200萬人次的檢測試劑，覆蓋80%以上疾病控制系統，極大的解決了一線醫護人員的診斷短缺的問題，有助於精準、快速地檢出患者是否感染新冠病毒，識別早期感染者，為疫情防控提供系統解決方案。
董事會認為，此項合作不但有利於公司抓住目前全球對抗疫情的市場機會，能夠為公司帶來一定的收益；而且可以充分發揮公司團隊在歐洲及東南亞地區沉澱的社會資源，使公司對於全球疫情的防控作出一份貢獻，履行企業的社會責任。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
